|
1
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lewis BP, Shih IH, Jones-Rhoades MW,
Bartel DP and Burge CB: Prediction of mammalian microRNA targets.
Cell. 115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
He L, He X, Lim LP, de Stanchina E, Xuan
Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al: A microRNA
component of the p53 tumour suppressor network. Nature.
447:1130–1134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dalmay T and Edwards DR: MicroRNAs and the
hallmarks of cancer. Oncogene. 25:6170–6175. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takamizawa J, Konishi H, Yanagisawa K,
Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y,
et al: Reduced expression of the let-7 microRNAs in human lung
cancers in association with shortened postoperative survival.
Cancer Res. 64:3753–3756. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yoon SO, Chun SM, Han EH, Choi J, Jang SJ,
Koh SA, Hwang S and Yu E: Deregulated expression of microRNA-221
with the potential for prognostic biomarkers in surgically resected
hepa-tocellular carcinoma. Hum Pathol. 42:1391–1400. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mraz M and Pospisilova S: MicroRNAs in
chronic lymphocytic leukemia: From causality to associations and
back. Expert Rev Hematol. 5:579–581. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Calin GA, Dumitru CD, Shimizu M, Bichi R,
Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al:
Frequent deletions and downregulation of micro-RNA genes miR15 and
miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci
USA. 99:15524–15529. 2002. View Article : Google Scholar
|
|
14
|
Calin GA, Ferracin M, Cimmino A, Di Leva
G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et
al: A MicroRNA signature associated with prognosis and progression
in chronic lymphocytic leukemia. N Engl J Med. 353:1793–1801. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Saito Y, Liang G, Egger G, Friedman JM,
Chuang JC, Coetzee GA and Jones PA: Specific activation of
microRNA-127 with down-regulation of the proto-oncogene BCL6 by
chromatin-modifying drugs in human cancer cells. Cancer Cell.
9:435–443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nakamura T, Canaani E and Croce CM:
Oncogenic All1 fusion proteins target Drosha-mediated microRNA
processing. Proc Natl Acad Sci USA. 104:10980–10985. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Parkin DM: Global cancer statistics in the
year 2000. Lancet Oncol. 2:533–543. 2001. View Article : Google Scholar
|
|
18
|
Kim JG, Kim TO, Bae JH, Shim JW, Kang MJ,
Yang K, Ting AH and Yi JM: Epigenetically regulated MIR941 and
MIR1247 target gastric cancer cell growth and migration.
Epigenetics. 9:1018–1030. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ushijima T, Nakajima T and Maekita T: DNA
methylation as a marker for the past and future. J Gastroenterol.
41:401–407. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ando T, Yoshida T, Enomoto S, Asada K,
Tatematsu M, Ichinose M, Sugiyama T and Ushijima T: DNA methylation
of microRNA genes in gastric mucosae of gastric cancer patients:
its possible involvement in the formation of epigenetic field
defect. Int J Cancer. 124:2367–2374. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yan H, Choi AJ, Lee BH and Ting AH:
Identification and functional analysis of epigenetically silenced
microRNAs in colorectal cancer cells. PLoS One. 6:e206282011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Esquela-Kerscher A and Slack FJ: OncomiRs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lujambio A, Calin GA, Villanueva A, Ropero
S, Sánchez-Cé-spedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso
MS, Faller WJ, et al: A microRNA DNA methylation signature for
human cancer metastasis. Proc Natl Acad Sci USA. 105:13556–13561.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Welch C, Chen Y and Stallings RL:
MicroRNA-34a functions as a potential tumor suppressor by inducing
apoptosis in neuro-blastoma cells. Oncogene. 26:5017–5022. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tazawa H, Tsuchiya N, Izumiya M and
Nakagama H: Tumor-suppressive MIR34a induces senescence-like growth
arrest through modulation of the E2F pathway in human colon cancer
cells. Proc Natl Acad Sci USA. 104:15472–15477. 2007. View Article : Google Scholar
|
|
27
|
Bommer GT, Gerin I, Feng Y, Kaczorowski
AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, et al:
p53-mediated activation of miRNA34 candidate tumor-suppressor
genes. Curr Biol. 17:1298–1307. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Corney DC, Flesken-Nikitin A, Godwin AK,
Wang W and Nikitin AY: microRNA-34b and microRNA-34c are targets of
p53 and cooperate in control of cell proliferation and
adhesion-independent growth. Cancer Res. 67:8433–8438. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Toyota M, Suzuki H, Sasaki Y, Maruyama R,
Imai K, Shinomura Y and Tokino T: Epigenetic silencing of
microRNA-34b/c and B-cell translocation gene 4 is associated with
CpG island meth-ylation in colorectal cancer. Cancer Res.
68:4123–4132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
He J, Xu Q, Jing Y, Agani F, Qian X,
Carpenter R, Li Q, Wang XR, Peiper SS, Lu Z, et al: Reactive oxygen
species regulate ERBB2 and ERBB3 expression via miR-199a/125b and
DNA methylation. EMBO Rep. 13:1116–1122. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lei H, Zou D, Li Z, Luo M, Dong L, Wang B,
Yin H, Ma Y, Liu C, Wang F, et al: MicroRNA-219–2–3p functions as a
tumor suppressor in gastric cancer and is regulated by DNA
methylation. PLoS One. 8:e603692013. View Article : Google Scholar
|
|
32
|
Yan X, Chen X, Liang H, Deng T, Chen W,
Zhang S, Liu M, Gao X, Liu Y, Zhao C, et al: miR-143 and miR-145
synergistically regulate ERBB3 to suppress cell proliferation and
invasion in breast cancer. Mol Cancer. 13:2202014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hayashi M, Inokuchi M, Takagi Y, Yamada H,
Kojima K, Kumagai J, Kawano T and Sugihara K: High expression of
HER3 is associated with a decreased survival in gastric cancer.
Clin Cancer Res. 14:7843–7849. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Begnami MD, Fukuda E, Fregnani JH,
Nonogaki S, Montagnini AL, da Costa WL Jr and Soares FA: Prognostic
implications of altered human epidermal growth factor receptors
(HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor
outcome. J Clin Oncol. 29:3030–3036. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Oshimo Y, Nakayama H, Ito R, Kitadai Y,
Yoshida K, Chayama K and Yasui W: Promoter methylation of cyclin D2
gene in gastric carcinoma. Int J Oncol. 23:1663–1670.
2003.PubMed/NCBI
|
|
36
|
Takano Y, Kato Y, Masuda M, Ohshima Y and
Okayasu I: Cyclin D2, but not cyclin D1, overexpression closely
correlates with gastric cancer progression and prognosis. J Pathol.
189:194–200. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Leone V, D’Angelo D, Rubio I, de Freitas
PM, Federico A, Colamaio M, Pallante P, Medeiros-Neto G and Fusco
A: MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting
CCND2, CXCR4, and SDF-1alpha. J Clin Endocrinol Metab.
96:E1388–E1398. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang L, Liu X, Jin H, Guo X, Xia L, Chen
Z, Bai M, Liu J, Shang X, Wu K, et al: miR-206 inhibits gastric
cancer proliferation in part by repressing cyclinD2. Cancer Lett.
332:94–101. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gong J, Li J, Wang Y, Liu C, Jia H, Jiang
C, Wang Y, Luo M, Zhao H, Dong L, et al: Characterization of
microRNA-29 family expression and investigation of their
mechanistic roles in gastric cancer. Carcinogenesis. 35:497–506.
2014. View Article : Google Scholar
|
